Premium
Large‐volume leukapheresis yields more viable CD34+ cells and colony‐forming units than normal‐volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells
Author(s) -
Abrahamsen J.F.,
Stamnesfet S.,
Liseth K.,
Hervig T.,
Bruserud O.
Publication year - 2005
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2004.04210.x
Subject(s) - leukapheresis , apheresis , cd34 , medicine , urology , peripheral blood , progenitor cell , nuclear medicine , platelet , andrology , surgery , stem cell , biology , genetics
BACKGROUND: Large‐volume leukapheresis (LVL) differs from normal‐volume leukapheresis (NVL) by increased blood flow and altered anticoagulation regimen. LVL is now regarded as a safe procedure for collection of peripheral blood progenitor cells (PBPCs), but it is not known whether the procedure will alter CD34+ cell quality or will be useful for patients who mobilize few CD34+ cells into peripheral blood. STUDY DESIGN AND METHODS: The results from 82 LVL and 125 NVL (4.0‐5.3 and 2.7‐3.5 times the patients’ blood volumes processed, respectively) were retrospec‐tively analyzed in altogether 112 consecutive patients with malignant diseases. RESULTS: The LVL yielded significantly more CD34+ cells (4.2 × 10 6 vs. 3.1 × 10 6 /kg, p = 0.006, all patients; and 1.8 × 10 6 vs. 1.3 × 10 6 /kg, p = 0.004, bad mobilizers) and significantly higher colony‐forming units (77 × 10 4 vs. 33 × 10 4 /kg; all patients and 33 × 10 4 vs. 20 × 10 4 /kg, p < 0.001, both groups). Significantly fewer leukapheresis procedures were required to obtain 2 × 10 6 CD34+ cells per kg (one vs. two, p = 0.001, all patients; and two vs. three, p = 0.009, bad mobilizers). No significant differences in CD34+ cell viability and time to hematologic recovery were observed between the patients who received PBPCs harvested by NVL and LVL. CONCLUSION: Although a median platelet loss of 36 percent can be expected, LVL can be recommended as the standard apheresis method for PBPC collections in patients with malignant diseases. LVL is particularly useful in patients who mobilize a low number of CD34+ cells into the peripheral blood.